Big Gains Expected in Microbiome Manufacturing by 2035, New Analysis Reveals

The microbiome manufacturing sector is quietly gathering steam, and if the latest projections are anything to go by, the next decade could be transformative. Roots Analysis has just published its updated outlook, predicting that the market valued at roughly USD 27 million back in 2023 could soar past USD 185 million by 2035.

If that sounds like a bold bet, its not. Over the past few years, treatments targeting the human microbiome have gone from being fringe science to serious contenders in mainstream healthcare. Approvals like Vowst and Rebyota have proven that therapies built around gut bacteria aren't just experimental, they're working, and theyre opening up an entirely new chapter in medicine.

That said, its not all smooth sailing. Manufacturing live biotherapeutic products isnt your typical pharmaceutical production job. These therapies involve delicate, living organisms that react badly to heat, contamination, even small variations in process. As a result, drug developers are increasingly leaning on contract manufacturers who know how to handle the complexity. It's safer, faster, and frankly, cheaper in the long run.

A Closer Look at Whats Driving the Microbiome Manufacturing Market

Several things are converging to push the microbiome sector forward. For starters, chronic illnesses are on the rise, and theres growing frustration with traditional treatments. At the same time, advances in genomics and bioengineering are making it easier (and cheaper) to create custom therapies based on an individuals microbiota.

Interestingly, Europe currently leads the microbiome manufacturing market by revenue, but if you look closely, North America is catching up. With big biotech hubs like Boston and San Francisco investing heavily, it's only a matter of time before the U.S. market sees a significant uptick.

Another under-the-radar trend? Smaller companies are dominating the field. Unlike giant pharma corporations weighed down by complex structures, smaller firms are nimble enough to innovate quickly, experiment with new approaches, and respond faster to changing science.

Market Highlights

Roots Analysis highlights a few key trends:

APIs are still king, taking up over half of market revenue in 2023.

Liquid formulations continue to dominate, but solid forms are starting to gain attention.

Pouches and sachets are the most common packaging no surprise, given how sensitive these products are.

The commercial manufacturing scale is outpacing clinical manufacturing by a wide margin.

The Companies to Watch

If youre keeping an eye on movers and shakers, names like Capsugel, Fujifilm Diosynth Biotechnologies, Arranta Bio, and Biose Industrie should be on your radar. These players are investing in smarter, faster manufacturing methods designed specifically for the challenges of microbiome-based therapies.

On a different note, partnerships between academic institutions, start-ups, and CMOs are starting to reshape the market as well. Expect a lot more collaboration moving forward, especially as science keeps evolving.

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the subject given. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way

Contact Details

Gaurav Chaudhary

Email: sales@rootsanalysis.com